Skip to main content
Bob Li, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

BobT.LiMD

Oncology New York, NY

Thoracic Cancer

Physician

Overview of Dr. Li

Dr. Bob Li is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of New South Wales Faculty of Medicine and has been in practice 11 years. He is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 464 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of Sydney
    University of SydneyMPH, 2012 - 2014
  • University of New South Wales Faculty of Medicine
    University of New South Wales Faculty of MedicineClass of 2006

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2015 - 2025

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial. 
    2019 ASCO Annual Meeting - 6/1/2019
  • A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Authored Content

  • We Need a Global System for Testing and Approving Cancer TreatmentsOctober 2022

Press Mentions

  • MSK Research Highlights, May 18, 2023
    MSK Research Highlights, May 18, 2023May 18th, 2023
  • 2-Year Follow-up Shows Sotorasib Significantly Prolongs Survival in Patients with Non-Small Cell Lung Cancer
    2-Year Follow-up Shows Sotorasib Significantly Prolongs Survival in Patients with Non-Small Cell Lung CancerApril 30th, 2023
  • ENHERTU® Approved in the U.S. As the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
    ENHERTU® Approved in the U.S. As the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung CancerAugust 11th, 2022
  • Join now to see all

Hospital Affiliations